Federal Register / Vol. 72, No. 78 / Tuesday April 24, 2007 / Notices 20343 

TABLE 1.—ESTIMATED RESPONDENT BURDEN—Continued 

Type of respondent Number of 

respondents 

Number of 

responses per 

respondent 

Estimated time 

per respondent 

(hours) 

Estimated total 

burden 

(hours) 

Medication Staff ......................................................................................... 4 1 1 hour ...............

(60 minutes) 

4 hours. 

Total Burden .............................................................................................. ........................ ........................ ........................... 589.5 hours. 

*Each direct caregiver staff person will be interviewed about multiple residents (approximately 9 each). These interviews will occur three 

times—at baseline, at 6 months and at 12 months for a total of 27 interviews. Direct caregiver staff and other facility staff we interview will be 

similar to certified nurse assistants. We do not include professional level staff in this category. 

Estimated Annual Costs to the Federal 

Government 

The total estimated one-time cost of 

this intervention implementation and 

related data collection to the federal 

government is $199,600. This funding 

will be used to support the cost of 

implementing the intervention, salary 

and fringe benefits for the research team 

to conduct the survey interview and indepth interview, costs for members of 

the research team to travel to each site, 

and the incentives paid to facilities for 

participation in the intervention. The 

project proposes to work with assisted 

living facilities with which the research 

team already has established 

relationships and familiarity and will 

attempt to minimize burden to the 

assisted living facility staff by being 

flexible to schedules and requirements 

of care practices within the facilities. 

Request for Comments 

In accordance with the above-cited 

Paperwork Reduction Act legislation, 

comments on AHRQ’s information 

collection are requested with regard to 

any of the following: (a) Whether the 

proposed collection of information is 

necessary for the proper performance of 

AHRQ health care research and health 

care information dissemination 

functions, including whether the 

information will have practical utility; 

(b) the accuracy of AHRQ’s estimate of 

burden (including hours and costs) of 

the proposed collection(s) of 

information; (c) ways to enhance the 

quality, utility, and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information upon the 

respondents, including the use of 

automated collection techniques or 

other forms for information technology. 

Dated: April 11, 2007. 

Carolyn M. Clancy, 

Director. 

[FR Doc. 07–2012 Filed 4–23–07; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–07–06BK] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

The Centers for Disease Control and 

Prevention (CDC) publishes a list of 

information collection requests under 

review by the Office of Management and 

Budget (OMB) in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

requests, call the CDC Reports Clearance 

Officer at (404) 639–5960 or send an email to omb@cdc.gov. Send written 

comments to CDC Desk Officer, Office of 

Management and Budget, Washington, 

DC or by fax to (202) 395–6974. Written 

comments should be received within 30 

days of this notice. 

Proposed Project 

Assessment of Occupational Exposure 

Management—New—Division of 

Healthcare Quality Promotion (DHQP), 

National Center for Preparedness, 

Detection, and Control of Infectious 

Diseases (NCPDCID), Centers for Disease 

Control and Prevention (CDC). 

Background and Brief Description 

The purpose of this project is to assess 

how healthcare facilities manage 

occupational blood exposures as part of 

a larger plan to prevent the transmission 

of blood borne pathogens. While the 

United States Public Health Service 

protocols on management of 

occupational exposure are widely 

distributed, the awareness and 

implementation of these protocols by 

providers of health services are 

unknown. 

In this project, CDC will randomly 

survey four types of healthcare facilities, 

acute care facilities, ambulatory surgery 

centers, long-term care facilities, and 

dialysis centers. The facility will be 

asked to complete the survey which 

asks questions about facility awareness 

and preparation; general occupational 

exposure management practices; 

occupational exposures to hepatitis B 

virus (HBV), hepatitis C virus (HCV), 

and human immunodeficiency virus 

(HIV); post-exposure prophylaxis; and 

exposure prevention measures. 

Facilities may complete the survey by 

paper and pencil or on the web. The 

results of the survey will be used to 

provide healthcare facilities with up-todate information on infection control. 

There are no costs to the respondents 

other than their time to complete the 

survey. The total estimated annualized 

burden hours are 1,773. 

Respondents Number of 

respondents 

Number of responses per 

respondent 

Average 

burden per response 

(in hours) 

Acute care facilities ...................................................................................................................... 865 1 20/60 

Ambulatory care facilities ............................................................................................................. 353 1 20/60 

Long-term care facilities .............................................................................................................. 3,634 1 20/60 

Dialysis Centers ........................................................................................................................... 468 1 20/60 


jlentini on PROD1PC65 with NOTICES
20344 Federal Register / Vol. 72, No. 78 / Tuesday April 24, 2007 / Notices 

Dated: April 18, 2007. 

Maryam Daneshvar, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. E7–7732 Filed 4–23–07; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

President’s Committee for People With 

Intellectual Disabilities; Notice of 

Meeting 

AGENCY: President’s Committee for 

People with Intellectual Disabilities 

(PCPID), Administration for Children 

and Families, HHS. 

ACTION: Notice of quarterly meeting. 

DATES: Monday, May 14, 2007, from 9 

a.m.–5 p.m. EST, and Tuesday, May 15, 

2007, from 9 a.m.–2 p.m. EST. The 

meeting will be open to the public. 

ADDRESSES: The meeting will be held in 

Room 800 of the Hubert H. Humphrey 

Building, 200 Independence Ave., SW., 

Washington, DC 20201. Individuals who 

will need accommodations for a 

disability in order to attend the meeting 

(e.g., interpreting services, assistive 

listening devices, materials in 

alternative format such as large print or 

Braille) should notify Kodie Ruzicka via 

e-mail at kruzicka@acf.hhs.gov, or via 

telephone at 202–205–7989 no later 

than May 1, 2007. PCPID will attempt to 

meet requests made after that date, but 

cannot guarantee availability. All 

meeting sites are barrier free. 

Meeting Registration: The meeting is 

open to the public, but attendance is 

limited to the space available. Persons 

wishing to attend this meeting must 

register by contacting Kodie Ruzicka at 

the e-mail address or telephone number 

listed in the ADDRESSES section of this 

notice by 12 p.m. EST on May 11, 2007. 

For those unable to participate in 

person, audio of the Monday, May 14 

proceedings may be accessed via 

telephone. Please use the above contact 

information for Kodie Ruzicka to obtain 

telephone and passcode information. 

Agenda: PCPID will meet to reappoint 

its members. They will also discuss 

possible content areas for the 2008 

Report to the President and will divide 

into subcommittees for that purpose. 

FOR FURTHER INFORMATION CONTACT: 

Sally D. Atwater, Executive Director, 

President’s Committee for People with 

Intellectual Disabilities, The Aerospace 

Center, Suite 701, 370 L’Enfant 

Promenade, SW., Washington, DC 

20447. Telephone: 202–619–0634, fax: 

202–205–9591. E-mail: 

satwater@acf.hhs.gov. 

SUPPLEMENTARY INFORMATION: PCPID 

acts in an advisory capacity to the 

President and the Secretary of Health 

and Human Services on a broad range 

of topics relating to programs, services 

and supports for persons with 

intellectual disabilities. PCPID, by 

Executive Order, is responsible for 

evaluating the adequacy of current 

practices in programs, services and 

supports for persons with intellectual 

disabilities, and for reviewing legislative 

proposals that impact the quality of life 

experienced by citizens with 

intellectual disabilities and their 

families. 

Dated: April 17, 2007. 

Sally D. Atwater, 

Executive Director, President’s Committee for 

People with Intellectual Disabilities. 

[FR Doc. E7–7759 Filed 4–23–07; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Summaries of Medical and Clinical 

Pharmacology Reviews of Pediatric 

Studies; Availability 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing the 

availability of summaries of medical 

and clinical pharmacology reviews of 

pediatric studies submitted in 

supplements for CELEBREX (celecoxib), 

COLAZAL (balsalazide), ELOXATIN 

(oxaliplatin), EMTRIVA (emtricitabine), 

SUPRANE (desflurane), and TOPROL–

XL (metoprolol). These summaries are 

being made available consistent with 

the Best Pharmaceuticals for Children 

Act (the BPCA). For all pediatric 

supplements submitted under the 

BPCA, the BPCA requires FDA to make 

available to the public a summary of the 

medical and clinical pharmacology 

reviews of the pediatric studies 

conducted for the supplement. 

ADDRESSES: Submit written requests for 

single copies of the summaries to the 

Division of Drug Information (HFD–

240), Center for Drug Evaluation and 

Research, Food and Drug 

Administration, 5600 Fishers Lane, 

Rockville, MD 20857. Please specify by 

product name which summary or 

summaries you are requesting. Send one 

self-addressed adhesive label to assist 

that office in processing your requests. 

See the SUPPLEMENTARY INFORMATION

section for electronic access to the 

summaries. 

FOR FURTHER INFORMATION CONTACT: 

Grace Carmouze, Center for Drug 

Evaluation and Research, Food and 

Drug Administration, 10903 New 

Hampshire Ave., Bldg. 22, rm. 6460, 

Silver Spring, MD 20993–0002, 301–

796–0700, e-mail: 

grace.carmouze@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

I. Background 

FDA is announcing the availability of 

summaries of medical and clinical 

pharmacology reviews of pediatric 

studies conducted for CELEBREX 

(celecoxib), COLAZAL (balsalazide), 

ELOXATIN (oxaliplatin), EMTRIVA 

(emtricitabine), SUPRANE (desflurane), 

and TOPROL–XL (metoprolol). The 

summaries are being made available 

consistent with section 9 of the BPCA 

(Public Law 107–109). Enacted on 

January 4, 2002, the BPCA reauthorizes, 

with certain important changes, the 

pediatric exclusivity program described 

in section 505A of the Federal Food, 

Drug, and Cosmetic Act (the act) (21 

U.S.C. 355a). Section 505A of the act 

permits certain applications to obtain 6 

months of marketing exclusivity if, in 

accordance with the requirements of the 

statute, the sponsor submits requested 

information relating to the use of the 

drug in the pediatric population. 

One of the provisions the BPCA 

added to the pediatric exclusivity 

program pertains to the dissemination of 

pediatric information. Specifically, for 

all pediatric supplements submitted 

under the BPCA, the BPCA requires 

FDA to make available to the public a 

summary of the medical and clinical 

pharmacology reviews of pediatric 

studies conducted for the supplement 

(21 U.S.C. 355a(m)(1)). The summaries 

are to be made available not later than 

180 days after the report on the 

pediatric study is submitted to FDA (21 

U.S.C. 355a(m)(1)). Consistent with this 

provision of the BPCA, FDA has posted 

on the Internet summaries of medical 

and clinical pharmacology reviews of 

pediatric studies submitted in 

supplements for CELEBREX (celecoxib), 

COLAZAL (balsalazide), ELOXATIN 

(oxaliplatin), EMTRIVA (emtricitabine), 

SUPRANE (desflurane), and TOPROL–

XL (metoprolol). See the SUPPLEMENTARY

INFORMATION section for electronic 

access to the summaries. Copies are also 

available by mail (see ADDRESSES). 


jlentini on PROD1PC65 with NOTICES